Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
CEFADROXIL
BRISTOL-MYERS SQUIBB CANADA
J01DB05
CEFADROXIL
500MG
CAPSULE
CEFADROXIL 500MG
ORAL
100
Prescription
FIRST GENERATION CEPHALOSPORINS
Active ingredient group (AIG) number: 0115958005; AHFS:
CANCELLED POST MARKET
2009-02-05
PRODUCT MONOGRAPH PR DURICEF* (CEFADROXIL) CAPSULES, 500 MG ANTIBIOTIC Bristol-Myers Squibb Canada Date of Preparation: 2365 Cote de Liesse October 25, 2004 St. Laurent PQ H4N 2M7 Control#: 094706 * TM of Bristol-Myers Squibb Company used under licence by Bristol-Myers Squibb Canada 1 PRODUCT MONOGRAPH DURICEF* (CEFADROXIL) Capsules, 500 mg THERAPEUTIC CLASSIFICATION ANTIBIOTIC ACTION AND CLINICAL PHARMACOLOGY DURICEF (cefadroxil) is a cephalosporin with bactericidal activity. _In vitro_ studies have shown that the antibacterial activity of the cephalosporins results from their ability to inhibit mucopeptide synthesis in the bacterial cell wall. INDICATIONS AND CLINICAL USE DURICEF (cefadroxil) may be indicated for the treatment of the following infections when caused by susceptible strains of the organisms indicated: - Acute uncomplicated urinary tract infections when caused by _E. coli_, Klebsiella species and some strains of _Proteus mirabilis_. - Skin and skin structure infections caused by _Staphylococcus aureus_ and/or group A beta- hemolytic streptococci. - Acute pharyngitis-tonsillitis, when caused by group A beta-hemolytic streptococci. - Lower respiratory tract infections, including pneumonia, caused by _S. pneumoniae (D._ _pneumoniae), S. Pyogenes_ (Group A-beta hemolytic streptococci), _K. pneumoniae_ and _S._ _aureus_. Appropriate bacteriological studies should be performed prior to and during therapy in order to identify and determine the susceptibility of the causative organism(s). CONTRAINDICATIONS DURICEF (cefadroxil) is contraindicated in patients with a known hypersensitivity to the cephalosporin group of antibiotics or to any component of the formulation. WARNINGS Before therapy with DURICEF is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to DURICEF, other cephalosporins, penicillins, or other drugs. If this product is to be given to penicillin-sensitive patients, caution should be exercised because cross-sensitivity am Soma hati kamili